Hypertension is highly prevalent in the dialysis population, and has been implicated in the pathogenesis of the observed excess of cardiovascular morbidity and mortality in these patients. Nevertheless, there are no reports on the clinical and biochemical determinants of both pulse pressure (PP) and mean arterial pressure (MAP) in dialysis populations. A total of 541 haemodialysed patients from 11 dialysis centres were included in the study. The demographic, clinical, and biological characteristics were recorded. Both pre-and postdialytic blood pressures (systolic and diastolic) were measured. PP and MAP were calculated. Mean predialytic PP was 67 ؎ 17 mm Hg and significantly decreased after dialysis (60 ؎ 18 mm Hg; P Ͻ 0.0001). In multivariate analysis, a 10 mm Hg increase in PP was positively associated with age (RR, 2.01; 95% CI, 1.35-5.01, for a 10-year increase in age), diabetes mellitus (RR, 1.08; 95% CI, 1.04 -1.14), interdialytic weight gain (IWG) (RR,
Introduction
Cardiovascular disease (CVD) is the major cause of mortality both in the general population and in patients with end-stage renal disease (ESRD) accounting for approximately 40% of all deaths in both demographic groups.
1,2 Nevertheless, compared to the general population, dialysis patients have disproportionately high rates of arteriosclerotic outcomes, and CVD mortality in this patient category is 10 to 20 times higher than in the general population.
3 Hypertension is highly prevalent in the dialysis population, 1,4 and has been implicated in the pathogenesis of the observed excess of cardiovascular morbidity and mortality in these patients. 5, 6 The pathophysiology of dialysis-associated hypertension is multifactorial. Several mechanisms (increased sympathetic activity, fluid retention, activation of the renin-angiotensin axis, etc) have been incriminated. Moreover, some clinical and biochemical parameters, including age, interdialytic weight gain, erythropoietin (EPO) treatment, and hyperparathyroidism have been also associated with hypertension in this patient category. 4 Blood pressure consists of both a steady component (mean arterial pressure, MAP) and a pulsatile component (pulse pressure, PP). Major determinants of MAP are ventricular ejection and peripheral vascular resistance. 7, 8 PP, the difference between systolic blood pressure (SBP) and diastolic blood pressure (DBP), is also made up of two major components, one due to ventricular ejection interacting with the viscoelastic properties of the large arteries and the other due to wave reflection. 7, 8 The distinction between the two components of blood pressure is clinically relevant because new evidence suggest that PP is a more sensitive measure of cardiovascular risk than other indices of blood pressure (DBP, SBP, and MAP). 9 Moreover, arterial stiffening
Journal of Human Hypertension is very pronounced in renal patients accounting for an increase in PP in this population compared to controls. 10 Nevertheless, there is no report on the clinical and biochemical determinants of both PP and MAP in the dialysis population. Such a knowledge may help physicians in the comprehensive approach of hypertension in this patient category. We reported baseline data of a prospective survey study in 541 hemodialysed patients. Blood pressure was measured and both PP and MAP were calculated to determine factors associated with the different components of blood pressure.
Patients and methods

Patients characteristics
A total of 541 patients with coronary heart disease were included in a prospective survey study of cardiovascular morbidity and mortality in April 2000. The demographic characteristics of the study population are depicted in Table 1 . All the dialysis centres in Bourgogne-Franche Comté were asked to participate in the study. The inclusion criteria included coronary heart disease for at least 3 months and the absence of acute illness at the time of the study.
Blood pressure
Predialytic blood pressure (SBP, DBP) was measured by a nurse using a semi-automatic device, based on an oscillometric method with the patient in a sitting position after resting for more than 5 min before starting the dialysis session. Postdialytic blood pressure was measured using the same method 10 min after the end of the dialysis session. Pulse pressure (SBP − DBP) was calculated. MAP was defined as DBP plus one-third of PP. The values used in analyses were the means of all predialysis during 1 week. Age, gender, dry weight, size, residual renal function, haemodialysis duration, weekly haemodialysis session duration, diabetes mellitus, smoking status, compliance, past history of cardiovascular events (CVE), binephrectomy or parathyroidectomy, antihypertensive drugs, and EPO use were assessed through anamnesis and medical records.
Residual renal function: Data on estimated urine volume were collected and reported as a dichotomous variable, less than or greater than 200 ml/24-h. Patients with estimated urine output of less than 200 ml/24 h were considered to have lost their residual renal function (RRF) whereas patients with estimated urine output greater than 200 ml/24 h were considered to have preserved RRF.
Compliance: Behavioural compliance was evaluated by physicians in each centre and categorised as good or moderate.
Smoking behaviour: With respect to smoking behaviour, subjects were categorised as current or former smokers and those who never smoked.
Primary renal disease: Primary renal disease was assessed through medical records and categorised as chronic glomerulonephritis, chronic interstitial nephritis, polycystic kidney disease, diabetes mellitus, nephroangiosclerosis, or undetermined.
Nutritional status: Normalised protein catabolism rate (nPCR) and albumin concentration were determined. Body mass index (BMI) was calculated (weight (kg)/height (m) 2 ).
Dialysis adequacy: Kt/V was assessed using Daugirdas 2 formula. Weekly dialysis time was also recorded.
Ultrafiltration: Ultrafiltration was calculated as the patient's weight at the beginning of each session minus the weight after the session, divided by the nephrologist's determined dry weight. Ultrafiltration was calculated on the basis of the average of all measurements in the study week.
Statistical analysis
Results are given as mean Ϯ s.d.
Initially, univariate analyses were carried out in order to examine the relationship between predialysis PP (or MAP), and a number of potential independent variables. Among the latter, covariates to enter multivariate analyses were selected as follows:
• Continuous variables were tested using Student's t-test or Mann-Whitney's non-parametric test.
• Categorical variables were tested using Pearson's chi-square, or Fisher's exact test.
The alpha threshold for covariate selection was 0.20. Such variables linked with PP (or MAP) with Pvalues less than 0.20 were retained for multivariate analyses, medical knowledge of the variables guiding the final choice. Selected covariates were entered into stepwise multiple-regression analysis.
Starting with as many covariates as were chosen (either statistically or otherwise), the software performed backwards stepwise selection, the limit to remove a covariate being a P-value of 0.10.
Results
Demographic characteristics of the population
Twenty-one patients with chronic arterial hypotension (predialysis SBP Ͻ100 mm Hg and/or postdialysis SBP Ͻ90 mm Hg) were excluded from analysis. The demographic characteristics and the laboratory values of the study population are shown in Table 1 .
Pulse pressure
Mean predialytic PP was 67 Ϯ 17 mm Hg and significantly decreased after dialysis (60 Ϯ 18 mm Hg; P Ͻ 0.0001).
In monovariate analysis, age (P = 0.001), antihypertensive drugs (P = 0.13), past history of coronary artery disease (P = 0.07), diabetes mellitus (P = 0.01), haemodialysis duration (P = 0.09), haemodialysis session duration (P = 0.02), interdialytic weight gain (IWG) (P = 0.002), albumin level (P = 0.05), RRF (P = 0.12), BMI (P = 0.04), and current smoking (P = 0.004) were positively associated with PP. Haemoglobin concentration (P = 0.01) and binephrectomy (P = 0.18) were negatively correlated with PP.
In multivariate analysis, a 10 mm Hg increase in PP was positively associated with age (RR, 2.01; 95% CI, 1.35-5.01, for a 10-year increase in age), diabetes mellitus (RR, 1.08; 95% CI, 1.04 -1.14), IWG (RR, 1.84; 95% CI, 1.07-3.18, for 1% increase in IWG), and current smoking (RR, 2.59; 95% CI, 1.13-5.92) and negatively with Hb concentration (RR, 0.92; 95% CI, 0.84 -0.99, for a 1 g/100 ml in Hb) ( Table 2) . 
Mean arterial pressure
Mean predialytic MAP was 98 Ϯ 15 mm Hg and significantly decreased after dialysis (91 Ϯ 16 mm Hg; P Ͻ 0.0001).
In monovariate analysis, age (P = 0.04), antihypertensive drugs (P = 0.12), past history of cerebrovascular disease (P = 0.08), nPCR (P = 0.05), albumin level (P = 0.06), RRF (P = 0.12), parathyroid hormone (PTH) adjusted for parathyroidectomy (P = 0.007), EPO treatment (P = 0.01), BMI (P = 0.04), and current smoking (P = 0.002) were associated with MAP.
In multivariate analysis, a 10 mm Hg increase in MAP was positively associated with PTH, adjusted for parathyroidectomy (RR, 1.32; 95% CI, 1.15-1.6, for a 50 ng/ml in PTH), EPO treatment (RR, 1.09; 95% CI, 1.03-1.16), and current smoking (RR, 1.87; 95% CI, 1.39-2.41) ( Table 3) .
Discussion
This study reports that, in a population of chronic, stable haemodialysis patients. PP and MAP are associated with different determinants. PP and MAP are related to different physiological mechanisms. Pulse pressure, the difference between peak SBP and end-DBP, represents the pressure increment over and above the existing DBP that results from ventricular contraction and ejection of arterial blood into the aorta. At any given ventricular ejection and heart rate, large artery stiffness determines PP. Pulse pressure, therefore, is the surrogate measurement of pulsatile opposition to blood flow during systole. In contrast, cardiac output and peripheral vascular resistance influence the MAP equation. In the presence of a normal cardiac output, MAP is thought to be the surrogate measure of static resistance to blood flow provided by arterioles during diastole. Besides these physiological differences, our study outlines the role of different clinical and biochemical determinants on these two components of blood pressure.
Previous studies have shown a progressive increase in blood pressure with aging, beginning in childhood and progressing throughout adulthood.
11
The aging process in humans is associated with progressive stiffening of the aortic and other elastic arteries. Age causes arterial elastin to decrease while collagen increases. 12 These vascular changes cause a substantial increase in ascending aortic PP. Systolic blood pressure increases with age due to aortic impedance and early return of wave reflections. In
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Current smoking was strongly associated with both MAP and PP in dialysis patients. Cigarette smoking has been previously associated with hypertension 14 or resistance to hypertensive drugs 15 in other populations. Moreover, nicotine administration has been associated with hypertension in rats. 16 Several mechanisms are probably involved in smoking-induced hypertension. Cigarette smoking is associated with a release of the sympathetic neurotransmitter, noradrenaline, as well as the adrenomedullary hormone adrenaline. 17 Furthermore, several clinical and experimental studies suggest that smoking interferes with prostacyclin and thromboxane A2 metabolism in the endothelium, 18, 19 as well as nitric oxide and endothelin-1. 20, 21 Moreover, the plasma concentration of the latter was found to be increased in smokers. 22 These mechanisms may contribute to increase vascular resistance and thus MAP. On the other hand, smoking-related macrovascular disease and arterial stiffness could account for the increased PP observed in smokers.
Remodelling of large arteries in ESRD patients is, in part, associated with hyperkinetic circulation and increased cardiac output. In these patients the haemodynamic effects of increased blood flow on the macrocirculation have been widely reported. 10 Our results confirm that factors associated with hyperkinetic circulation and fluid overload are also associated with increased PP. In our study, IWG was highly correlated with PP. The role of interdialytic weight gain and volume overload in the physiopathology of hypertension in dialysis patients is controversial. Many studies have shown no correlation between IWG and blood pressure. 23, 24 Salem et al, 25 in an epidemiological study of change in blood pressure over 1 year, showed no relationship between interdialytic weight gain and blood pressure. Cheigh et al, 26 using 24-h ambulatory blood pressure monitoring, showed that the predialysis blood pressure change did not correlate with weight gain during the interdialytic period. Dionisio et al 27 showed a strong correlation between total body water measured by bioelectrical impedance and mean 24-h blood pressure. The present study strongly supports the contention that fluid overload is an important factor affecting blood pressure in haemodialysis patients. Haemoglobin concentration was also found to be negatively associated with predialytic PP. Anaemia is associated with a hyperdynamic circulation associated with increased stroke volume. The increase in ventricular ejection and heart rate may account for the role of anaemia in increasing PP.
There may be a correlation between an increase in intracellular calcium levels induced by PTH excess and hypertension. In a recent study using ambulatory blood pressure monitoring, the PTH level was the major determinant of blood pressure. 28 Moreover, recent observations linking the correction of hyperparathyroidism by either vitamin D administration 29 or parathyroidectomy 30 in chronic dialysis patients, resulting in a lower blood pressure, have supported this hypothesis. In our study, we found a correlation between PTH levels and predialysis MAP, but not PP.
We also found a positive relationship between recombinant human EPO (rhuEPO) therapy and MAP. Hypertension has been associated with the treatment of anaemia with rhuEPO in chronic haemodialysis patients. 31 Thus, the European Multicenter Study 32 reported that EPO (250 U/kg IV weekly) increased MAP by 4 mm Hg at 6 months, but not any further after 1 year. The Canadian Multicenter Study 33 also reported that EPO (300 U/kg IV weekly) did not alter SBP at rest; however DBP increased from 12 mm Hg after 6 months. These results are consistent with the association between rhuEPO and MAP, and not PP. The pathophysiology of EPO-related hypertension is complex, but primarily involves an increase in vascular resistance. A direct vasopressor effect of EPO has been suggested, 34 but other authors have reported that EPO is not directly vasoconstrictive, but enhances vascular responsiveness in vitro by increasing the release of endothelin and vasoconstrictor prostanoids and decreasing the release of prostacyclin. [35] [36] [37] The present observations have some limitations principally because of their cross-sectional and observational nature, and interventional studies are necessary to delineate the precise roles of various factors associated with increased PP or MAP. Indeed, an association between two factors do not imply a causal relationship and such a crosssectional analysis must be regarded as hypothesisgenerating.
Pulse pressure and MAP are associated with different clinical parameters. Most of these factors are potentially reversible. In the view of a predominant role for PP in cardiovascular risk, smoking cessation, correction of anaemia and limitation of IWG should be important challenges for physicians who are caring for dialysis patients. 
References
